CA2235686C - Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine - Google Patents

Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine Download PDF

Info

Publication number
CA2235686C
CA2235686C CA002235686A CA2235686A CA2235686C CA 2235686 C CA2235686 C CA 2235686C CA 002235686 A CA002235686 A CA 002235686A CA 2235686 A CA2235686 A CA 2235686A CA 2235686 C CA2235686 C CA 2235686C
Authority
CA
Canada
Prior art keywords
indolin
spiro
compound
tert
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002235686A
Other languages
English (en)
Other versions
CA2235686A1 (fr
Inventor
Loic Foulon
Georges Garcia
Claudine Serradeil-Le Gal
Gerard Valette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9512533A external-priority patent/FR2740136B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of CA2235686A1 publication Critical patent/CA2235686A1/fr
Application granted granted Critical
Publication of CA2235686C publication Critical patent/CA2235686C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention a pour objet des dérivés d'indolin-2-one de formule (I) dans laquelle W repésente un groupe -CH2- ou -SO2; Cy constitue avec le carbone auquel il est lié un cycle hydrocarboné non aromatique en C3-C12, saturé ou insaturé, éventuellement condensé ou susbtitué par un ou plusieurs groupes (C1-C7)alkyles, lesdits groupes pouvant substituer une ou plusieurs fois le même atome de carbone ou par un spirocycloalkyle en C3-C6; T représente un (C1-C4)alkylène éventuellement interrompu par un (C3-C6)cycloalkylène, lesdits alkylènes étant éventuellement substitués une ou plusieurs fois sur le même atome de carbone par un (C1-C3)alkyle; ou bien T représente une liaison directe; Z représente notamment un groupe amino; R1 et R2 ainsi que R3 et R4 sont soit l'hydrogène, soit des substituants, tels que par exemple un halogène, un alkyle, etc. Application: médicaments ayant une affinité pour les récepteurs de la vasopressine et/ou de l'ocytocine.
CA002235686A 1995-10-24 1996-10-24 Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine Expired - Fee Related CA2235686C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9512533A FR2740136B1 (fr) 1995-10-24 1995-10-24 Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
FR95/12533 1995-10-24
PCT/FR1996/001666 WO1997015556A1 (fr) 1995-10-24 1996-10-24 Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine

Publications (2)

Publication Number Publication Date
CA2235686A1 CA2235686A1 (fr) 1997-05-01
CA2235686C true CA2235686C (fr) 2007-06-26

Family

ID=38279097

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002235686A Expired - Fee Related CA2235686C (fr) 1995-10-24 1996-10-24 Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine

Country Status (1)

Country Link
CA (1) CA2235686C (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700641B2 (en) 2005-04-11 2010-04-20 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
US7799798B2 (en) 2005-04-11 2010-09-21 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US8450358B2 (en) 2009-06-29 2013-05-28 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700641B2 (en) 2005-04-11 2010-04-20 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
US7799798B2 (en) 2005-04-11 2010-09-21 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
US8106087B2 (en) 2005-04-11 2012-01-31 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8916580B2 (en) 2008-10-17 2014-12-23 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US9458178B2 (en) 2008-10-17 2016-10-04 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8415370B2 (en) 2008-10-17 2013-04-09 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8883840B2 (en) 2009-06-29 2014-11-11 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US8450358B2 (en) 2009-06-29 2013-05-28 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US9480677B2 (en) 2009-06-29 2016-11-01 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US8742109B2 (en) 2009-10-14 2014-06-03 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US9260446B2 (en) 2009-10-14 2016-02-16 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US9695185B2 (en) 2009-10-14 2017-07-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Also Published As

Publication number Publication date
CA2235686A1 (fr) 1997-05-01

Similar Documents

Publication Publication Date Title
US5994350A (en) 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands
JP3330958B2 (ja) インドリン−２−オン誘導体、その製造方法、およびこれを含有する薬学的組成物
AU662960B2 (en) N-sulphonyl-2-oxoindole derivatives having affinity for vasopressin and/or ocytocin receptors
JP3263081B2 (ja) バソプレシンおよび／またはオシトシン作動薬および／または拮抗薬としての窒素基によって３位において置換されている１，３−ジヒドロインドール−２−オン誘導体
NZ264122A (en) Substituted 1-benzenesulphonyl dihydroindolones; medicaments
CA2129214A1 (fr) Derives de la 1-phenylsulfonyl-1,3-dihydro-2h-benzimidazol-2-one
CA2235686C (fr) Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine
US7910584B2 (en) 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof
US20090275580A1 (en) 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof
MXPA98003269A (en) Derivatives of 3-espiro-indolin-2-ona as ligands of vasopressin and / or oxitoc receptors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131024